Danaher Co. (NYSE:DHR) Shares Sold by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC reduced its position in shares of Danaher Co. (NYSE:DHR) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,980 shares of the conglomerate’s stock after selling 390 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Danaher were worth $1,373,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. FMR LLC boosted its position in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the last quarter. Fisher Asset Management LLC grew its stake in Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after purchasing an additional 116,299 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. raised its position in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on DHR. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Raymond James cut their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Guggenheim began coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Finally, StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Trading Up 0.1 %

Shares of NYSE:DHR opened at $245.95 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company’s 50-day moving average price is $235.33 and its 200 day moving average price is $253.45. The company has a market cap of $177.65 billion, a PE ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.